Back to Search
Start Over
Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study
- Source :
- Lancet Oncology, Lancet Oncology, 2022, 23 (1), pp.161-171. ⟨10.1016/S1470-2045(21)00603-3⟩, Lancet Oncology, Elsevier, 2022, 23 (1), pp.161-171. ⟨10.1016/S1470-2045(21)00603-3⟩
- Publication Year :
- 2022
- Publisher :
- HAL CCSD, 2022.
-
Abstract
- International audience; Background: Hepatocellular carcinoma is a frequent consequence of alcohol-related liver disease, with variable incidence among heavy drinkers. We did a genome-wide association study (GWAS) to identify common genetic variants for alcohol-related hepatocellular carcinoma. Methods: We conducted a two-stage case-control GWAS in a discovery cohort of 2107 unrelated European patients with alcohol-related liver disease aged 20–92 years recruited between Oct 22, 1993, and March 12, 2017. Cases were patients with alcohol-related hepatocellular carcinoma diagnosed by imaging or histology. Controls were patients with alcohol-related liver disease without hepatocellular carcinoma. We used an additive logistic regression model adjusted for the first ten principal components to assess genetic variants associated with alcohol-related hepatocellular carcinoma. We did another analysis with adjustment for age, sex, and liver fibrosis. New candidate associations (pandlt;1 × 10−6) and variants previously associated with alcohol-related hepatocellular carcinoma were evaluated in a validation cohort of 1933 patients with alcohol-related liver disease aged 29–92 years recruited between July 21, 1995, and May 2, 2019. We did a meta-analysis of the two case–control cohorts. Findings: The discovery cohort included 775 cases and 1332 controls. Of 7 962 325 variants assessed, we identified WNT3A-WNT9A (rs708113; p=1·11 × 10−8) and found support for previously reported regions associated with alcohol-related hepatocellular carcinoma risk at TM6SF2 (rs58542926; p=6·02 × 10−10), PNPLA3 (rs738409; p=9·29 × 10−7), and HSD17B13 (rs72613567; p=2·49 × 10−4). The validation cohort included 874 cases and 1059 controls and three variants were replicated: WNT3A-WNT9A (rs708113; p=1·17 × 10−3), TM6SF2 (rs58542926; p=4·06 × 10−5), and PNPLA3 (rs738409; p=1·17 × 10−4). All three variants reached GWAS significance in the meta-analysis: WNT3A-WNT9A (odds ratio 0·73, 95% CI 0·66–0·81; p=3·93 × 10−10), TM6SF2 (1·77, 1·52–2·07; p=3·84×10−13), PNPLA3 (1·34, 1·22–1·47; p=7·30 × 10−10). Adjustment for clinical covariates yielded similar results. We observed an additive effect of at-risk alleles on alcohol-related hepatocellular carcinoma. WNT3A-WNT9A rs708113 was not associated with liver fibrosis. Interpretation: WNT3A-WNT9A is a susceptibility locus for alcohol-related hepatocellular carcinoma, suggesting an early role of the Wnt–β-catenin pathway in alcohol-related hepatocellular carcinoma carcinogenesis.
- Subjects :
- Adult
Male
Carcinoma, Hepatocellular
Genotype
[SDV]Life Sciences [q-bio]
[SDV.CAN]Life Sciences [q-bio]/Cancer
Polymorphism, Single Nucleotide
Young Adult
[SDV.CAN] Life Sciences [q-bio]/Cancer
Wnt3A Protein
Humans
Genetic Predisposition to Disease
Aged
Aged, 80 and over
Liver Neoplasms
Genetic Variation
Middle Aged
Wnt Proteins
[SDV] Life Sciences [q-bio]
Oncology
Case-Control Studies
Phospholipases A2, Calcium-Independent
Female
Alcohol-Related Disorders
Acyltransferases
Genome-Wide Association Study
Subjects
Details
- Language :
- English
- ISSN :
- 14702045 and 14745488
- Database :
- OpenAIRE
- Journal :
- Lancet Oncology, Lancet Oncology, 2022, 23 (1), pp.161-171. ⟨10.1016/S1470-2045(21)00603-3⟩, Lancet Oncology, Elsevier, 2022, 23 (1), pp.161-171. ⟨10.1016/S1470-2045(21)00603-3⟩
- Accession number :
- edsair.doi.dedup.....69b5ee707d87fbe03980906d8bc92ff4
- Full Text :
- https://doi.org/10.1016/S1470-2045(21)00603-3⟩